GTS Securities’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-4,847
Closed -$388K 1495
2026
Q1
$388K Sell
4,847
-616
-11% -$50.8K 0.01% 911
2025
Q4
$466K Buy
+5,463
New +$448K 0.02% 827
2025
Q2
Sell
-4,678
Closed -$339K 1336
2025
Q1
$339K Sell
4,678
-65
-1% -$4.65K 0.01% 884
2024
Q4
$351K Sell
4,743
-24,203
-84% -$1.69M 0.02% 791
2024
Q3
$1.91M Buy
28,946
+22,848
+375% +$1.66M ﹤0.01% 1598
2024
Q2
$563K Buy
+6,098
New +$540K ﹤0.01% 2595
2024
Q1
Sell
-28,404
Closed -$2.39M 4013
2023
Q4
$2.17M Buy
28,404
+25,248
+800% +$1.76M ﹤0.01% 1596
2023
Q3
$219K Buy
+3,156
New +$254K ﹤0.01% 3341

Other funds holding EW

GTS Securities's EW Position: Q2 2026 in Review

GTS Securities sold out of Edwards Lifesciences (EW) in Q2 2026, closing a stake of 4,847 shares — an estimated $388K sold.

GTS Securities first reported a position in EW in Q3 2023 and held it in 8 quarters. The position peaked at $2.17M in Q4 2023. 1,334 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • GTS Securities reported no remaining Edwards Lifesciences position as of Q2 2026 after selling out during the quarter.
  • GTS Securities sold 4,847 Edwards Lifesciences shares in Q2 2026, an estimated $388K.
  • GTS Securities first reported a position in Edwards Lifesciences in Q3 2023 and held it in 8 quarters.
  • GTS Securities's Edwards Lifesciences position peaked at $2.17M in Q4 2023.
  • 1,334 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.